# TuHURA Biosciences, Inc.: overview HURA · Nasdaq · CIK 1498382 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/hura.md) · [Financials](/companies/hura/financials.md) · [Filings](/companies/hura/filings.md) · [Insiders](/companies/hura/insiders.md) Latest reported revenue: [$0](/filings/0001193125-26-227245.md) for Q1 FY2026, three months to 2026-03-31, from the 10-Q filed May 15, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-227245). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0 d](/filings/0001193125-25-281539.md) | [0.0 d](/filings/0001193125-26-134950.md) | [0.0](/filings/0001193125-26-227245.md) | [0.0 d](/filings/0000950170-25-108972.md) | [0.0 d](/filings/0001193125-25-281539.md) | [0.0 d](/filings/0001193125-26-134950.md) | [0.0](/filings/0001193125-26-227245.md) | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.54)](/filings/0001193125-25-281539.md) | not reported | [(0.15)](/filings/0001193125-26-227245.md) | [(0.21)](/filings/0001193125-26-350451.md) | [(0.14)](/filings/0001193125-25-281539.md) | not reported | [(0.13)](/filings/0001193125-26-227245.md) | [(0.14)](/filings/0001193125-26-350451.md) | | Free cash flow | $m | [(1.9) d](/filings/0000950170-24-127199.md) | [(2.6) d](/filings/0001193125-26-134950.md) | [(4.8)](/filings/0001193125-26-227245.md) | [(6.3) d](/filings/0001193125-26-350451.md) | [(11.1) d](/filings/0001193125-25-281539.md) | [(5.6) d](/filings/0001193125-26-134950.md) | [(4.5)](/filings/0001193125-26-227245.md) | [(8.8) d](/filings/0001193125-26-350451.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Operating margin (operating income / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2023 (2023-06-30) | FY2023 (2023-12-31) | FY2024 (2024-06-30) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | [0.0](/filings/0000950170-25-047921.md) | not reported | [0.0](/filings/0001193125-26-134950.md) | [0.0](/filings/0001193125-26-134950.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | [(2.47)](/filings/0000950170-25-047921.md) | not reported | [(1.21)](/filings/0001193125-26-134950.md) | [(0.63)](/filings/0001193125-26-134950.md) | | Free cash flow | $m | not reported | [(12.0)](/filings/0000950170-25-047921.md) | not reported | [(14.8)](/filings/0001193125-26-134950.md) | [(27.7)](/filings/0001193125-26-134950.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/hura/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $5.3m | 2,267,901 | | Added +193,673 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $3.8m | 1,621,042 | | Added +1,322,855 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.6m | 690,088 | | Reduced −1,760,168 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.1m | 484,219 | | Reduced −502,703 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $1.1m | 454,535 | | New +454,535 | | [AQR CAPITAL MANAGEMENT LLC](/funds/1167557.md) | 2026-06-30 | $993.6k | 424,600 | | Reduced −182,568 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $587.8k | 251,186 | | Reduced −35,947 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $543.6k | 232,319 | | New +232,319 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $440.9k | 188,404 | | Reduced −324,509 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $383.5k | 163,891 | | New +163,891 | ## Recent filings [All 925 filings](/companies/hura/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-16 | 21:00 ET | [8-K](/filings/0001193125-26-424228.md) | 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-424228 | | 2026-09-24 | 21:00 ET | [8-K](/filings/0001193125-26-401140.md) | 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-401140 | | 2026-09-17 | 21:00 ET | [8-K](/filings/0001193125-26-394473.md) | 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-394473 | | 2026-09-17 | 13:00 ET | [8-K/A](/filings/0001193125-26-393847.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-393847 | | 2026-09-16 | 21:00 ET | [8-K](/filings/0001193125-26-393206.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-393206 | | 2026-09-04 | 21:00 ET | [8-K](/filings/0001193125-26-383797.md) | 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-383797 | | 2026-08-28 | 22:01 ET | [SCHEDULE 13D/A](/filings/0000897069-26-001732.md) | Ownership report, active investor, amended | 0000897069-26-001732 | | 2026-08-21 | 21:00 ET | [8-K](/filings/0001193125-26-361272.md) | 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001193125-26-361272 | | 2026-08-19 | 21:00 ET | [8-K](/filings/0001193125-26-357087.md) | 3.02 Unregistered sale of equity; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-357087 | | 2026-08-14 | 12:00 ET | [10-Q](/filings/0001193125-26-350451.md) | Quarterly report, period 2026-06-30 | 0001193125-26-350451 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-134950.md), filed Mar 31, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1498382 - Tickers: HURA - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.